Storia in 2 fonti

Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery

Absci Corporation begins dosing patients in the first human trial of ABS-201, an AI-designed antibody for hair loss, reaching clinic in just 24 months.

Raccontata da

cryptobriefing.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

cryptobriefing.comStai leggendo1 mese fa

Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery

Absci starts human trial of ABS-201, monoclonal antibody designed with generative AI, in 24 months. For CTOs, it's the first proof of AI drug discovery compressing timelines; AMD partnership ($20M) signals generative AI penetration in regulated biotech.

originale

benzinga.com1 mese fa

Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Absci (NASD

Absci reported positive interim Phase 1 ABS-201 data and priced a $100 million stock offering to advance development.

Leggi questa versione →

Timeline cronologica

domenica 21 giugno 2026·cryptobriefing.com
Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery
Absci Corporation begins dosing patients in the first human trial of ABS-201, an AI-designed antibody for hair loss, reaching clinic in just 24 months.
mercoledì 24 giugno 2026·benzinga.com
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Absci (NASD
Absci reported positive interim Phase 1 ABS-201 data and priced a $100 million stock offering to advance development.